弥漫性大B细胞淋巴瘤的临床病理及免疫组织化学研究

A clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma.

作者信息

Tao Kun, Zhu Xiongzeng, Xu Weiling, Chen Zhongwei, Lu Hongfen

机构信息

Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China.

出版信息

Zhonghua Bing Li Xue Za Zhi. 2002 Apr;31(2):112-5.

PMID:12419155

Abstract

OBJECTIVE

To study the clinicopathologic and immunohistochemical features of diffuse large B-cell lymphoma (DLBCL) and the significance of immunohistochemistry in diagnosis and differential diagnosis of DLBCL.

METHODS

60 cases of DLBCL were studied and immunohistochemical staining for LCA, L26, BLA-36, CD30, bcl-6 were carried out with the EnVision 2 step method.

RESULTS

The age range of 76.7% (46/60) patients was 40 - 70 years. The location of the lesion includes nodal and extranodal sites. 90.0% (54/60) were in clinical stages of II (24/54), III (21/54), IV (9/54). Histopathologic morphology presented as centroblastic (88.3%, 53/60), immunoblastic (3.3%, 2/60), anaplastic large B cell type (3.3%, 2/60) and T cell rich B cell type (5.0%, 3/60). Immunostaining showed 100% (60/60) DLBCL were positive for LCA, L26, BLA36, 3.3% (2/60) DLBCL positive for CD30, 95% (57/60) expressed bcl-6 protein.

CONCLUSIONS

DLBCL is an aggressive lymphoma which shows cytologic variability from case to case. The evaluation of pathologic features and immunohistochemistry in DLBCL are useful and practical for diagnostic purposes, but cannot delineate distinctive morphologic subtypes.

摘要

目的

研究弥漫性大B细胞淋巴瘤（DLBCL）的临床病理及免疫组化特征，以及免疫组化在DLBCL诊断和鉴别诊断中的意义。

方法

对60例DLBCL进行研究，采用EnVision两步法对LCA、L26、BLA-36、CD30、bcl-6进行免疫组化染色。

结果

76.7%（46/60）患者年龄在40 - 70岁。病变部位包括淋巴结及结外部位。90.0%（54/60）处于临床Ⅱ期（24/54）、Ⅲ期（21/54）、Ⅳ期（9/54）。组织病理学形态表现为中心母细胞型（88.3%，53/60）、免疫母细胞型（3.3%，2/60）、间变性大B细胞型（3.3%，2/60）和富于T细胞的B细胞型（5.0%，3/60）。免疫染色显示100%（60/60）的DLBCL对LCA、L26、BLA36呈阳性，3.3%（2/60）的DLBCL对CD30呈阳性，95%（57/60）表达bcl-6蛋白。